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Protein tyrosine sulfation is a post-translational modiﬁcation best known for regulating
extracellular protein–protein interactions. Tyrosine sulfation is catalysed by two Golgi-resi-
dent enzymes termed tyrosylprotein sulfotransferases (TPSTs) 1 and 2, which transfer
sulfate from the cofactor PAPS (30-phosphoadenosine 50-phosphosulfate) to a context-
dependent tyrosine in a protein substrate. A lack of quantitative tyrosine sulfation assays
has hampered the development of chemical biology approaches for the identiﬁcation of
small-molecule inhibitors of tyrosine sulfation. In the present paper, we describe the
development of a non-radioactive mobility-based enzymatic assay for TPST1 and TPST2,
through which the tyrosine sulfation of synthetic ﬂuorescent peptides can be rapidly
quantiﬁed. We exploit ligand binding and inhibitor screens to uncover a susceptibility of
TPST1 and TPST2 to different classes of small molecules, including the anti-angiogenic
compound suramin and the kinase inhibitor rottlerin. By screening the Published Kinase
Inhibitor Set, we identiﬁed oxindole-based inhibitors of the Ser/Thr kinase RAF (rapidly
accelerated ﬁbrosarcoma) as low-micromolar inhibitors of TPST1 and TPST2.
Interestingly, unrelated RAF inhibitors, exempliﬁed by the dual BRAF/VEGFR2 inhibitor
RAF265, were also TPST inhibitors in vitro. We propose that target-validated protein
kinase inhibitors could be repurposed, or redesigned, as more-speciﬁc TPST inhibitors to
help evaluate the sulfotyrosyl proteome. Finally, we speculate that mechanistic inhibition
of cellular tyrosine sulfation might be relevant to some of the phenotypes observed in
cells exposed to anionic TPST ligands and RAF protein kinase inhibitors.
Introduction
Like tyrosine phosphorylation [1], reversible tyrosine sulfation is a critical covalent modiﬁcation that
occurs post-translationally on proteins [2]. Originally identiﬁed more than half a century ago in sul-
fated ﬁbrinogen and gastrin [3], tyrosine sulfation occurs on a wide range of secreted polypeptides in
multicellular eukaryotes and involves the transfer of a negatively charged sulfate group from the
sulfate donor PAPS (30-phosphoadenosine-50-phosphosulfate) to a phenolic tyrosine residue. Tyrosine
sulfation is catalysed by two Golgi-associated membrane enzymes termed tyrosylprotein sulfotrans-
ferases 1 and 2 (TPST1 and 2), and sulfation leads to biologically relevant changes in a large number
of protein activities [2]. For example, sulfation can change the afﬁnity of extracellular protein–protein
interactions, such as those involved in chemotaxis [4], and host–pathogen interactions [5]. It also con-
trols the proteolytic processing of both bioactive peptides [6,7] and secreted antibodies [8], and multi-
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site tyrosine sulfation can change the function of several blood-coagulation regulators, including factor VIII
[9,10]. Interest in the pathophysiological analysis and therapeutic targeting of tyrosine sulfation was heightened
by the ﬁnding that N-terminal chemokine receptor tyrosine sulfation in the HIV G-protein coupled receptor
CCR5 [11,12] plays a crucial role in coat binding and viral infection. Earlier studies had implicated tyrosine sul-
fation in the proteolytic control of the complement cascade component through decreased activity of C4 [13],
the generation of gastrin from progastrin [14], and in regulating the binding of amino-terminal sulfated
P-selectin glycoprotein ligand-1 (PSGL-1) to P-selectin [15]. Interestingly, the binding of L-selectin on lympho-
cytes to mucin-like glycoproteins on endothelial cells is also regulated by sulfation, although the sialyl LewisX
surface antigen is modiﬁed by a distinct carbohydrate 6-O sulfotransferase [16].
TPST1 was originally puriﬁed from bovine adrenal medulla [17,18], and distinct human genes encoding
TPST1 and TPST2 have been cloned [19], with expression patterns varying markedly in both cells and tissues
[20–22]. Both enzymes are believed to reside in the trans-Golgi compartment of the secretory pathway, and as
type II transmembrane-containing enzymes with >85% sequence similarity in the intracellular catalytic
domains, which are luminal-facing for substrate modiﬁcation [19,21,22]. TPSTs interact with the sulfate-donor
cofactor PAPS and an appropriate (often acidic) tyrosine-containing protein substrate. Recent experiments
suggest that TPST1 and TPST2 might function as homo- or heterodimers [23,24], providing regulatory oppor-
tunities for the control of site-speciﬁc sulfation among substrates. In general, tyrosine sulfation occurs in an
acidic context in proteins and model substrates [2,18,24–26], although some, including the bioactive protein
gastrin, lack acid residues adjacent to the site of sulfation [14]. Analysis of a variety of synthetic peptides and
intact proteins conﬁrms that TPST1 and TPST2 can also control site-speciﬁc sulfation on multiple tyrosine
residues, which are often clustered, consistent with a processive mechanism of modiﬁcation [7,27], or direction-
ally distributed towards the substrate N-terminus [20,28]. Crystal structures of TPST1 complexed with substrate
peptides that are sulfated with different efﬁciencies have also been reported, and comparative analysis suggests
differential substrate preferences for acidic residues adjacent to the site of modiﬁcation [24,29]. Structural com-
parison suggests a shared catalytic mechanism and substrate-binding energetics, driven by charge-based
dynamic interactions. Bioinformatic analysis hints at a substantial and complex tyrosine sulfoproteome [30,31],
hence uncovering the extent, substrate determinants and biological function of tyrosine-sulfated proteins
remains a high-priority technical challenge for mass spectrometry (MS)-based proteomics [32].
The analysis of tyrosine sulfation currently relies heavily on genetic and relatively low-throughput MS-based
analysis, and only a few low-afﬁnity inhibitors of TPSTs have been reported [33–35]. Moreover, due to a lack
of chemical tool compounds, biological sulfation remains an understudied process relying on non-speciﬁc cyto-
toxic compounds, such as chlorate, to induce non-speciﬁc effects on sulfation [36]. The similarity between the
sulfotransferase cofactor PAPS and the phosphate donor ATP (utilised by protein kinases) raises questions as
to whether PAPS-dependent sulfotransferases might be broad inhibitory targets for new or repurposed small
molecules that target nucleotide-binding sites, especially well-studied families of compounds such as protein
kinase inhibitors. Moreover, the mode of substrate peptide recognition observed in substrate- and cofactor-
bound TPST2 structures closely resembles that established for the insulin-receptor tyrosine kinase bound to a
tyrosine-containing (YMXM) substrate and an ATP analogue [37], inviting further comparison between TPSTs
and the highly druggable protein kinase superfamily [38,39].
Analysis of TPST-based catalysis using small molecules remains in its infancy and is currently hampered by a
lack of rapid, ﬂexible, and reliable assays with which to screen for suitable inhibitors. Conventional procedures
employ 35S-based detection of sulfated tyrosine in synthetic peptides [18,21,34] or, increasingly, rely on gas-
phase MS-based detection of sulfated peptides [35,40,41]. Both of these approaches have technical drawbacks,
and can be time-consuming, although 35S-based peptide sulfation by TPST2 was used to discover the ﬁrst low-
afﬁnity reversible TPST2 inhibitors from a combinatorial library of aldehyde-linked heterocyclic compounds
[34]. Recently, indirect ﬂuorescent assays have been reported, including a PAPS depletion/reconstitution
approach to monitor sulfate transfer [28] and continuous TPST1 and 2 assays reporting ﬂuorescence-induced
peptide sulfation [35]. The latter approach monitors peptide sulfation over relatively long time periods and
requires inﬂexible positioning of the ﬂuorophore relative to the modiﬁed tyrosine and ﬂanking amino acid sulfa-
tion determinants. Nonetheless, such assays can be employed to discover small-molecule inhibitors in screens,
with several anionic compounds recently identiﬁed and cross-validated from commercial libraries [33,35].
In the present paper, we describe differential scanning ﬂuorimetry (DSF) and sulfation assays that permit
real-time analysis of TPST1- and TPST2-mediated peptide sulfation, allowing us to evaluate TPST interactions
with a variety of ligands and small-molecule inhibitors. PAPS-dependent sulfation of peptides leads to a
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charge-induced mobility change, driven through intrinsic properties of a sulfotyrosine-containing substrate.
Sulfation is detected by a real-time mobility shift using a ﬂuorescent microﬂuidic assay originally developed for
the detection of peptide tyrosine phosphorylation [42]. In conjunction with analytical DSF, we identiﬁed a
variety of known ligands as new TPST1 and TPST2 inhibitors, including the promiscuous protein kinase
inhibitor rottlerin and a family of oxindole-based RAF (rapidly accelerated ﬁbrosarcoma) kinase inhibitors
from the Published Kinase Inhibitor Set (PKIS). In a related paper, published back-to-back with the present
study, we demonstrate that some of these compounds also inhibit the oligosaccharide sulfotransferase activity
of heparan sulfate 2-O sulfotransferase [43], a related PAPS-dependent enzyme. Finally, chemically distinct
inhibitors with activity towards the proto-oncogenic kinase RAF, exempliﬁed by the dual BRAF/VEGFR2
inhibitor RAF265 (CHIR-265), were discovered to be more speciﬁc TPST inhibitors in vitro. We propose that
kinase inhibitors might be discovered through further screening, by chemical repurposing, or even redesigned
to create new classes of TPST inhibitor. Moreover, we speculate that inhibition of cellular tyrosine sulfation by
some of the compounds evaluated in the present study might contribute to the phenotypes observed in cells
exposed to RAF kinase inhibitors.
Experimental
Materials and methods
Chemicals and compounds
All standard biochemicals were purchased from either Melford or Sigma and were of the highest analytical
quality that could be obtained. PAPS (adenosine 30-phosphate 50-phosphosulfate, lithium salt hydrate), APS
(adenosine 50-phosphosulfate, sodium salt), PAP (adenosine 30–50-diphosphate, disodium salt), CoA (coenzyme
A, sodium salt) dephosphoCoA (30-dephosphoCoA, sodium salt hydrate), ATP (adenosine 50-triphosphate, dis-
odium salt hydrate), ADP (adenosine 50-diphosphate, disodium salt), AMP (adenosine 50-monophosphate,
sodium salt), GTP (guanosine 50-triphosphate, sodium salt hydrate), or cAMP (adenosine 30,50-cyclic mono-
phosphate, sodium salt) were all purchased from Sigma and stored at −80°C to ensure maximal stability.
Rottlerin, suramin, aurintricarboxylic acid, and all named kinase inhibitors were purchased from either Sigma,
BD laboratories, Selleck, or Tocris.
Cloning, protein puriﬁcation, and protein analysis
DNA encoding human TPST1 (residues Lys43–Leu360) and TPST2 (residues Gly43–Leu359) enzymes lacking
the transmembrane domains was ampliﬁed by PCR and cloned into pOPINF (OPPF-UK) to produce recom-
binant protein containing an N-terminal 6xHis tag and a 3C protease cleavage site. Recombinant TPST1 and
TPST2 proteins were expressed in BL21 (DE3) pLysS Escherichia coli (Novagen); expression was induced with
0.4 mM IPTG for 18 h at 37°C, and protein was isolated from inclusion bodies and refolded as described [44].
In brief, cells were resuspended in 3 ml of ice-cold lysis buffer [50 mM Tris–Cl (pH 8.0), 10 mM MgCl2, 1 mM
DTT supplemented with cOmplete, EDTA-free, protease inhibitor cocktail tablets (Roche)] per gram of E. coli
cell pellet and ﬂash-frozen with liquid nitrogen. Cells were disrupted by sonication; inclusion bodies were col-
lected by centrifugation for 1 h at 10 000xg at 4°C and washed in ice-cold WB1 (50 mM Tris–Cl (pH 8.0),
100 mM NaCl, 10 mM EDTA, and 1% (v/v) Triton X-100) followed by WB2 (20 mM Tris–Cl (pH 8.0),
200 mM NaCl, and 1 mM EDTA). Inclusion bodies were resuspended in SB (100 mM Tris–Cl (pH 8.0), 6 M
guanidine hydrochloride, 5 mM EDTA, and 10 mM DTT) and incubated at 4°C with constant agitation. SB
buffer was supplemented with fresh DTT (10 mM DTT) after 12 h and incubated for 2 h at room temperature.
Insoluble material was removed by centrifugation (1 h, 60 000xg, 4°C), and the supernatant was concentrated
by ultraﬁltration (Amicon Ultra-15 centrifugal ﬁlter unit, 10 kDa cut-off ) and then diluted 10-fold with buffer
A (100 mM Na-acetate (pH 4.5), 6 M guanidine hydrochloride, and 10 mM DTT). A 5 ml aliquot of concen-
trated TPST (∼150 mg) was slowly added (using a peristaltic pump) while mixing with a magnetic stirrer to 1 l
of pre-chilled refolding buffer, which comprised 50 mM Tris–Cl (pH 8.5), 500 mM guanidine hydrochloride,
10 mM NaCl, 0.4 mM KCl, 0.1 mM EDTA, 0.14 mM n-dodecyl β-D-maltoside, 5 mM reduced glutathione
(GSH), and 2.5 mM oxidised glutathione (GSSG). The refolding mixture was then incubated for 20 h at 4°C
without mixing and precipitated protein was subsequently removed by centrifugation. Soluble TPST protein
was then puriﬁed by sequential immobilised metal afﬁnity chromatography and size-exclusion chromatography
(SEC) using a HiLoad 16/600 Superdex200 column (GE Healthcare) equilibrated in 50 mM Tris–Cl (pH 7.4),
100 mM NaCl, and 10% (v/v) glycerol. Glutathione-S-transferase (GST)-tagged CC4-tide (EDFEDYEFDG) was
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cloned into pOPINJ (OPPF-UK) and afﬁnity-puriﬁed from BL21 (DE3) pLysS E. coli using Glutathione
Sepharose 4B (GE Healthcare) and SEC. The tyrosine kinase EphA3, comprising the kinase domain and the
juxtamembrane region with an N-terminal 6xHis-tag, was expressed in pLysS E. coli from pET28a LIC, and
puriﬁed using Ni-NTA agarose and gel ﬁltration, as described recently [42]. Halo-FGF7 was puriﬁed as previ-
ously described [45].
SDS–PAGE and immunoblotting
After the assay, proteins were denatured in Laemmli sample buffer, heated at 95°C for 5 min and then analysed
by SDS–PAGE with 10% (v/v) polyacrylamide gels. Gels were stained and destained using a standard Coomassie
Brilliant Blue protocol. To evaluate protein sulfation and phosphorylation by immunoblotting, standard western
blotting procedures were followed using monoclonal anti-sulfotyrosine antibody clone Sulfo-1C-A2 (Millipore)
generated using a phage display procedure and sulfotyrosine selection peptide antigens [46] in the presence of
appropriate positive and negative controls, and modiﬁcations visualised using the ECL reagent.
Differential scanning ﬂuorimetry assays
Thermal shift/stability assays (TSAs) were performed with a StepOnePlus Real-Time PCR machine (Life
Technologies) using the Sypro-Orange dye (Invitrogen) and thermal ramping between 20 and 95°C in 0.3°C
step intervals per data point to induce denaturation in the presence or absence of various biochemical and
small-molecule inhibitors [47,48]. TPST1 and TPST2 were assayed at a ﬁnal concentration of 5 mM in 50 mM
Tris–HCl (pH 7.4) and 100 mM NaCl. The ﬁnal DMSO concentration in the presence or absence of the indi-
cated concentrations of ligand was no higher than 4% (v/v). None of the test compounds analysed in the
absence of TPSTs were found to interfere with ﬂuorescent detection of Sypro-Orange binding. Normalised data
were processed using the Boltzmann equation to generate sigmoidal denaturation curves, and average Tm/ΔTm
values were calculated as described [48,49] using the GraphPad Prism software.
EZ Reader II-based peptide sulfation assays
Fluorescently tagged peptides used in TPST sulfotransferase assays were derived from the human
physiological substrate sequences where noted. A 5-FAM ﬂuorophore, with a maximal absorbance of
495 nm and a maximal emission absorbance of 520 nm that could be detected in an EZ Reader
via LED-induced ﬂuorescence, was covalently coupled to the free N-terminus of each peptide.
CC4-tide (5-FAM-EDFEDYEFDG-CONH2 and the equivalent peptide lacking the single acceptor
tyrosine residue, 5-FAM-EDFEDFEFDG-CONH2), were modiﬁed from the human Complement C4 protein
[13], ﬁbroblast growth factor 7 (FGF7, 5-FAM-ERHTRSYDYMEGGD-CONH2), and C–C motif chemokine
receptor 8 (CCR8, 5-FAM-TTVTDYYYPDIFSS-CONH2), and P-selectin glycoprotein ligand-1 (PSGL1,
5-FAM-TEYEYLDYDFLPETE-CONH2) peptides were derived from the appropriate human sequences (site of
tyrosine sulfation shaded in bold). Peptides were synthesised using solid-phase Fmoc chemistry and after
HPLC puriﬁcation (>95%), the expected intact peptide mass was conﬁrmed by MALDI-TOF mass spectrom-
etry (Pepceuticals, Leicester, U.K.). The PerkinElmer LabChip EZ II Reader system [50], 12-sipper chip
and CR8 coating, assay separation buffer, and a synthetic ﬂuorescent Ephrin A3 substrate (Ephrin A3-tide,
5-FAM-EFPIYDLPAKK-CONH2) were all purchased from PerkinElmer. Pressure and voltage settings were
adjusted manually to afford optimal separation of tyrosine-sulfated and non-sulfated peptides. Individual sulfa-
tion assays were performed in a 384-well plate in a volume of 80 μl in the presence of the indicated concentra-
tion of PAPS (Sigma–Aldrich), 50 mM HEPES (pH 7.4), 0.015% (v/v) Brij-35, and 5 mM MgCl2 (unless
speciﬁed otherwise), and the degree of peptide sulfation was directly calculated by the EZ Reader software by
differentiating sulfopeptide : peptide ratios. The activity of TPST proteins in the presence of inhibitors was
quantiﬁed by monitoring the amount of sulfopeptide generated over the assay time relative to the control assay
with no additional inhibitor molecule. Data were normalised with respect to these control assays, with sulfate
incorporation into the peptide limited to ∼20% to prevent depletion of PAPS and to ensure assay linearity. Km
and IC50 values were determined by nonlinear regression analysis using the Graphpad Prism software
Biochemical and small-molecule screening by DSF and TPST enzyme assay
The PKIS chemical library (designated with SB, GSK, or GW preﬁxes) comprising 367 largely ATP-competitive
kinase inhibitors, covering 31 chemotypes originally knowingly designed to inhibit 24 distinct protein kinases
[51,52], was stored frozen as a 10 mM stock in DMSO at −80°C. This inhibitor library is characterised as
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highly drug-like (∼70% with molecular mass <500 Da and clogP values <5). For initial screening, compounds
pre-dissolved in DMSO were pre-incubated with TPST1 or TPST2 for 10 min, and sulfotransferase reactions
were initiated by the addition of the universal sulfate donor PAPS. For inhibition assays, competition assays, or
individual IC50 value determination, the appropriate compound range was prepared by serial dilution in the
appropriate solvent and added directly into the assay to the indicated ﬁnal concentration. All control experi-
ments contained 4% (v/v) DMSO.
Molecular docking analysis
Rottlerin, GW305074X, suramin, and RAF265 were built using Spartan16 (https://www.wavefun.com) and
energy-minimised using the Merck molecular forceﬁeld. GOLD 5.2 (CCDC Software;) was used to dock mole-
cules [53], with the binding site deﬁned as 10 Å around the 50-phosphorous atom of PAP, using co-ordinates
from human TPST1 PDB ID: 5WRI [24]. A generic algorithm with ChemPLP as the ﬁtness function [54] was
used to generate 10 binding-modes per ligand in HS2ST. Protons were added to the protein. Default settings
were retained for the ‘ligand ﬂexibility’ and ‘ﬁtness and search options’; however, GA settings were changed
manually to 200%.
Results
Analysis of human TPST1 and TPST2 using a reliable TSA
To drive the development of new approaches to assay and inhibit protein tyrosine sulfation, we developed a
DSF assay to examine the thermal stability of TPST1 or TPST2 in the presence or absence of biochemical
Figure 1. Analysis of puriﬁed recombinant 6His-TPST proteins.
(A) Biochemical structure of PAPS- and PAPS-related compounds. (B) Coomassie blue staining of puriﬁed recombinant
6His-TPST enzymes: 1 mg of TPST1 and 2 were analysed by SDS–PAGE after puriﬁcation to near homogeneity. (C) TSA, and
calculation of Tm, for TPST1 (5 mM) in the presence of 0.5 mM PAPS (red) or 0.5 mM APS (blue); buffer control is in black.
(D) ΔTm for TPST1 in the presence of PAPS and APS, as measured by DSF, data derived from (C). ΔTm values were calculated
by subtracting the control Tm value (buffer, no nucleotide) from the measured Tm value. (E) As for (C) but using TPST2. (F) As
for (D), but employing TPST2. (G) Analysis of PAPS-dependent thermal stabilisation of TPST1 and TPST2. TSA employing
TPST1 or TPST2 proteins (5 mM) was measured in the presence of the indicated concentration of PAPS. ΔTm values were
calculated by DSF, as described above.
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ligands (Figure 1A). We puriﬁed recombinant soluble human 6His-tagged TPST1 and TPST2 catalytic domains
(amino acids 43–360 and 43–559, respectively, lacking the transmembrane domain) from bacterial inclusion
bodies to near homogeneity (Figure 1B). After refolding from guanidine hydrochloride into a Tris-based buffer,
TPST thermal stability and unfolding proﬁles were measured in the presence of the known sulfated cofactor
PAPS, or the dephosphorylated precursor APS, whose phosphorylation at the 30-position on the adenine ring
by APS kinase generates PAPS in cells. Heating of TPST1 and TPST2 generated a typical heat-induced unfold-
ing proﬁle with both TPST1 and TPST2 exhibiting almost identical Tm values (formally, the temperature at
which 50% of the protein is unfolded based on ﬂuorescence) of ∼40°C (Figure 1C,E). In both cases, inclusion
of PAPS in the unfolding assay induced a shift in the Tm value, suggesting that both enzymes were folded
and could bind to a physiological cofactor. In the case of TPST1, PAPS (but not APS) induced a ΔTm value of
∼3°C (Figure 1C,D), whereas TPST2 stability shifted by ∼9°C in the presence of PAPS, but not APS
(Figure 1E,F). A side-by-side comparison of TPST1 and TPST2 over a range of PAPS concentrations demon-
strated concentration-dependent effects on TPST stability, with a more marked shift in TPST2 stability at all
concentrations tested (Figure 1G). We next compared thermal unfolding in the presence of a panel of
nucleotide-based cofactors. These experiments demonstrated a lack of signiﬁcant thermal shift by Mg2+ ions,
APS, AMP, or cAMP. In contrast, ADP, PAP, CoA, acetyl CoA, and GTP all induced marked stabilisation of
both TPST1 and TPST2 at near stoichiometric concentrations in the assay, suggestive of high-afﬁnity binding.
In contrast with CoA, dephospho-CoA, which lacks a 30-phosphoadenine group, was unable to induce thermal
shifts in either TPST1 or 2, as established for APS, in which the 30-phosphoadenine group is also absent. In the
case of ATP, ADP, and GTP, TPST1 and TPST2 shifts were abolished in the presence of Mg2+ ions, presumably
reﬂecting the very high afﬁnity of this divalent cation for these nucleotides [48] (Supplementary Figure S1A,B).
A novel microﬂuidic assay to quantify real-time peptide sulfation by TPST1
and TPST2
Thermal and enzymatic screening assays can generate complementary information to help evaluate ligand
binding [55]. To extend our thermal analysis of TPST ligand binding to include real-time analysis of sulfate
transfer, and help progress our eventual goal of discovering TPST1 and TPST2 inhibitors, we developed a novel
enzyme assay for kinetic analysis of peptide tyrosine sulfation. The basic requirement of this assay was that it
should report the enzymatic incorporation of sulfate onto a tyrosine residue of a synthetic peptide substrate
with a high signal-to-noise ratio and be rapid, repeatable, and with relatively high throughput. Current proto-
cols to monitor tyrosine sulfation generally involve 35S-based enzyme regeneration or intrinsic ﬂuorescence
assays, which are often unsuitable for kinetic or high-throughput analysis using different peptide substrates,
and are prone to artefacts if compounds or cofactors that interfere with ﬂuorescence detection are employed.
However, as established below, our novel assay permits rapid real-time detection of non-radioactive sulfate
incorporation into synthetic peptides.
Synthetic peptides derived from human substrates are in vitro TPST1 and/or
TPST2 substrates
To evaluate context-speciﬁc sulfation kinetics for TPST1 and TPST2, we synthesised a panel of peptides posses-
sing tyrosine-containing sequences found in human proteins previously reported to be sulfated on tyrosine [2]
and developed an assay to quantify peptide sulfation. The assay comprises a putative substrate peptide (contain-
ing a tyrosine in an acid context and culminating in an amide group), TPST1 or TPST2, and the PAPS cofactor
(Figure 2A). To facilitate the detection of both sulfated and non-sulfated substrates in the same assay using a
microﬂuidic platform, we appended an N-terminal ﬂuorophore (5-FAM) to the peptide. Since tyrosylsulfate
(singly charged under the assay conditions) and tyrosylphosphate (doubly charged) are chemically similar, and
can potentially induce charge-based differences in peptide mobility when covalently attached to tyrosine, we
reasoned that this assay would be able to detect sulfation in a similar way to that previously established for
phosphorylation by Ser/Thr and Tyr kinases [42,56,57]. As shown in Figure 2B, incubation of a
5-FAM-conjugated 10-mer tyrosine-containing peptide from human complement C4 protein with TPSTs led
to the appearance of an electrophoretically distinct product (P) when compared with the unmodiﬁed substrate
(S). Different ratios of product to substrate were detected when TPST1 or TPST2 was included in the assay, but
no product was detected with buffer and PAPS alone, suggesting that the new product was a tyrosine-sulfated
peptide (Figure 2B).
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).2440
Biochemical Journal (2018) 475 2435–2455
https://doi.org/10.1042/BCJ20180266
We next compared the ability of TPST1 and TPST2 to modify the CC4 peptide (termed hereafter CC4-tide)
in a kinetic assay, monitoring the real-time appearance of the sulfated peptide by detecting the increase in
product peak height in a duplicate assay format. As shown in Figure 2C, TPST1 was much more efﬁcient at
modifying CC4-tide, inducing near-stoichiometric modiﬁcation after 1 h. The rate of CC4-tide sulfation by
TPST1 was responsive to divalent cations and could be increased 6- to 10-fold by including Mg2+ ions or Mn2+
ions in the buffer (Supplementary Figure S3A), despite a lack of detectable Mg2+ binding to TPST1 (or TPST2)
by DSF (Supplementary Figure S1A,B), consistent with previous studies [18,28,35]. In contrast, over the same
time and at the same concentration in the assay, puriﬁed TPST2 only sulfated CC4-tide to a stoichiometry of
∼20%. We next assessed whether TPST1 or TPST2 sulfated a ﬂuorescent 14-mer peptide derived from human
FGF7, which contains a single known site of tyrosine sulfation corresponding to Tyr27 in the mature growth
factor [58]. Using this new assay, we were unable to detect FGF7-tide sulfation by TPST2, although TPST1
induced ∼70% peptide sulfation over the assay time course (Figure 2D). Interestingly, CCR8-tide, which was
derived from the human CCR8 sequence, was even more rapidly sulfated by TPST1 than FGF7-tide, although
it was not modiﬁed noticeably by TPST2 (Figure 2E). In marked contrast, a distinct ﬂuorescent 14-mer
sequence derived from human PSGL1 was rapidly, and stoichiometrically sulfated by both TPST1 and TPST2
(Figure 2F), conﬁrming that these enzymes possess overlapping, as well as distinct, substrate speciﬁcities in
vitro. We also found that the rate of TPST1-catalysed sulfation of FGF7, CCR8 and, to a much smaller extent,
Figure 2. Detection of tyrosylprotein sulfotransferase activity using a direct microﬂuidic mobility shift assay and
ﬂuorescent peptide substrates.
(A) Schematic representation of PAPS-dependent sulfate incorporation into a tyrosine residue of a substrate. The sequence of
the synthetic single Tyr-containing peptide (CC4-tide, containing a ﬂuorescent 5-FAM group at the N-terminus) is shown above
the native human CC4 protein sequence. (B) TPST1 and TPST2-dependent tyrosine sulfation alters the microﬂuidic mobility of
CC4-tide. Separation of the higher-mobility, sulfated (product, P) peptide from the lower-mobility (substrate, S) peptide occurs
through a difference in their net charge. (C–F) Time-dependent tyrosine sulfation of CC4-tide (C) or ﬂuorescently labelled
tyrosine-containing substrate peptides derived from human FGF7 (D), CCR8 (E), or PSGL1 (F) proteins. Direct peptide sulfation
was calculated by measuring the ratio of substrate peptide to sulfo-peptide at the indicated time points after adding the PAPS
cofactor. All assays were performed at room temperature (20°C) using 2 mM ﬁnal concentration of the appropriate ﬂuorescent
peptide substrate, 500 mM PAPS, and 0.4 mM TPST1 or TPST2 in the presence of 5 mM MgCl2.
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PSGL1 was enhanced by divalent cations, with a clear activating preference for Mn2+ ions (Supplementary
Figure S3B–D). In contrast, and as established for CC4-tide, TSPT2 was essentially inactive towards FGF7 and
CCR8 in the presence and absence of divalent cations, although divalent Mn2+ ions and, to a lesser extent,
Mg2+ ions activated TPST2 (and TPST1) when PSGL1 was employed as the substrate (Supplementary
Figure S3B–D).
As a test of the suitability of our assay to derive a reported kinetic parameter, we employed an appropriate
concentration of TPST1 and TPST2, so that the degree of peptide sulfation was linear over the time course of
the reaction. Under these conditions, the Km value for PAPS in a TPST1-dependent CC4-tide assay was 6.6 ±
1.9 μM (Supplementary Figure S2), consistent with previous literature reports of 2–5 μM for TPST1 [18,25] or
12 μM for TPST2 obtained from transfected CHO cell medium [34] or ∼5 μM for recombinant TPST2 isolated
from baculovirus-infected insect cells [35].
Substrate and cofactor speciﬁcity for model TPST1 and TPST2 substrates
To investigate TPST site speciﬁcity, we conﬁrmed that the single Tyr residue in CC4 represents the site of cova-
lent modiﬁcation identiﬁed in the mobility assay, by generating a peptide in which Tyr was substituted for a
chemically analogous, but non-sulfatable, Phe residue. As shown in Figure 3A,B, PAPS-dependent CC4-tide
sulfation probably occurs on Tyr, because the Phe-substituted peptide was not modiﬁed by incubation with
TPST1 (or TPST2). To conﬁrm sulfate and phosphate cofactor speciﬁcity in the assay, we evaluated sulfation
and phosphorylation of the same CC4-tide substrate using either TPST1 or the tyrosine kinase Ephrin A3.
Importantly, Ephrin A3 generated a modiﬁed (phosphorylated) CC4 product peptide in the presence of ATP,
but not PAPS, whereas TPST1 generated a modiﬁed (sulfated) product peptide only in the presence of PAPS,
but not ATP (Figure 3C). The electrophoretic mobility of sulfated (TPST1-generated) or phosphorylated
Figure 3. Changes in ﬂuorescent peptide mobility are a consequence of TPST-catalysed tyrosine sulfation.
Mobility analysis of TPST1-dependent peptide sulfation for (A) CC4-tide or (B) CC4-tide in which the Tyr acceptor site is
mutated to Phe (Tyr741Phe). Recombinant TPST1 enzyme (0.4 mM) was assayed using 2 mM peptide substrate ± 10 mM PAPS
as sulfate donor. (C) Dual detection of tyrosine phosphorylation or tyrosine sulfation of CC4-tide. TPST1 (0.2 mM) or EphA3
tyrosine kinase (0.3 mM) were incubated with 2 mM CC4-tide in the presence of 500 mM PAPS (sulfate donor) or 500 mM ATP
(phosphate donor). (D) Lack of tyrosine sulfation of a distinct tyrosine-containing EphA3 substrate peptide by TPST1 or
2. Assay conditions were as for (C).
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(EphA3-generated) CC4 peptides relative to the non-modiﬁed peptide was very similar in our microﬂuidic
assay conditions, consistent with similar physiochemical properties of anionic sulfotyrosine and phosphotyro-
sine formed in the assay. Finally, we conﬁrmed the reported preference for tyrosine sulfation of peptide sub-
strates in the context of an N-terminal acidic residue (which is targeted electrostatically to the cationic active
site) by showing that a tyrosine kinase (TK) peptide substrate optimised for EphA3 phosphorylation was not
modiﬁed by TPST1 or TPST2, presumably because it lacked an acidic residue at the –1 position relative to Tyr,
although this did not prevent phosphorylation by EphA3 kinase in the presence of Mg-ATP (Figure 3D).
TPST1 and TPST2 sulfate tyrosine in recombinant sulfoacceptor proteins
Detection of quantitative tyrosine sulfation using real-time microﬂuidics represents a new approach to study
this covalent modiﬁcation in vitro. To unambiguously conﬁrm sulfation by TPST1 and TPST2 using a comple-
mentary technique, we used immunoblotting with a monoclonal antibody that speciﬁcally recognises sulfated
tyrosine in intact proteins. Initially, we generated a recombinant protein consisting of GST fused to the
CC4-tide sequence (EDFEDYEFDG) that was developed for TPST1 and TPST2 mobility-based enzyme assays
(Figures 2 and 3). As detailed in Figure 4A, this GST fusion protein became sulfated on tyrosine only after
incubation with TPSTs, and this modiﬁcation required PAPS in the assay. Consistently, GST was not detectably
sulfated under any condition, conﬁrming that the CC4-tide sequence was the target of both enzymes. Site spe-
ciﬁcity in the assay was conﬁrmed by mutation of Tyr to Phe in the GST fusion protein, which abolished detec-
tion by the sulfotyrosine antibody (Figure 4B). As a further control, we demonstrated that GST-CC4-tide could
become Tyr phosphorylated, but not Tyr sulfated, after incubation with Ephrin A3 and Mg-ATP at the same
tyrosine sulfated by TPST1/2 in GST-CC4-tide (Figure 4C, note detection of pTyr in EphA3 protein due to
autophosphorylation). This experiment also demonstrates unequivocally that the modiﬁcation-speciﬁc anti-
bodies can differentiate between sulfated and phosphorylated forms of the GST-CC4-tide protein. We also con-
ﬁrmed that full-length recombinant FGF7 was speciﬁcally modiﬁed by TPST1, but not by TPST2 in vitro,
consistent with side-by-side kinetic analysis of TPST1 and TPST2 FGF7-tide sulfation, which also suggested a
2-fold enhancement of recombinant FGF7 sulfation when TPST1 and TPST2 were both included in the assay
(Figures 2D and 4D). Given the known interaction between exogenously expressed TPST1 and TPST2 in the
Golgi compartment [23], we evaluated this latter observation using a ﬂuorescent FGF7 peptide, conﬁrming that
the rate and extent of peptide sulfation by TPST1 was enhanced in a dose-dependent manner by inclusion of
TPST2 in the assay (Figure 4E).
Analysis of TPST inhibition by biochemicals and the protein kinase inhibitor
rottlerin
The ability of ﬂuorescent peptide substrates to report TPST1- and TPST2-directed tyrosine sulfation in a plate-
based assay format allowed us to develop an enzyme screen for the analysis and discovery of small-molecule
TPST inhibitors. Based on the relative ease of puriﬁcation and highly stable activity towards multiple substrates,
we focused our biochemical screening studies on TPST1. As detailed in Figure 5A, the TPST ligands PAP,
CoA, dephospho-CoA, and ATP were all able to inhibit PAPS-dependent sulfation of ﬂuorescent CC4-tide by
TPST1 in vitro. The IC50 values for inhibition ranged from low to high μM. This ﬁnding is consistent with
the ability of PAP (ΔTm =∼10°C) and CoA (ΔTm =∼11°C), the two most potent inhibitors in the enzyme
assay, to interact with and stabilise TPST1 (and TPST2) in thermal shift assays. Interestingly, the ability of PAP
(IC50 = 1.5 μM) and CoA (IC50 = 87 μM) to inhibit TPST1 sulfation activity was highly sensitive to the concen-
tration of PAPS in the assay, with peptide sulfation in the assay increasing (less inhibition) as a function of
increasing PAPS, even taking into account the increases in enzyme activity induced by high levels of PAPS
(Figure 5B,C). In contrast, weak TPST1 inhibition by ATP and dephospho-CoA was largely insensitive to an
increase in PAPS levels in the assay, suggesting that it was likely to represent weak or non-competitive enzyme
binding (Figure 5D,E).
Several literature reports suggest that TPST1/2 are inhibited by nucleotide and non-nucleotide compounds in
vitro [35,59,60]. Using quantitative TPST1 and 2 enzyme assays, we identiﬁed that the broad-spectrum kinase
inhibitor rottlerin, which was originally described as a ‘speciﬁc’ cellular PKC inhibitor [61], but later revealed
to be a non-speciﬁc protein kinase inhibitor [62], inhibited PAPS-dependent TPST1 and TPST2 with single-
digit micromolar IC50 values (Figure 6A). We also evaluated the clinically applied orphan compound suramin
[63] and the DNA polymerase inhibitor aurintricarboxylic acid [64] as TPST inhibitors (Figure 6C),
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demonstrating inhibition with low-micromolar IC50 values, validating recent independent ﬁndings [35].
Consistently, we conﬁrmed that rottlerin binding also induced a positive TPST1 and TPST2 thermal shift
(Figure 6B), although the degree of stabilisation relative to ATP was lower than predicted, given the potent
inhibitory effect of rottlerin on TPST1 and TPST2 enzyme activity in vitro.
Multiple RAF kinase inhibitors target TPST catalytic activity in vitro
The provocative chemical and structural similarities between CoA, PAP, ATP, and PAPS (Figure 1A), combined
with the inhibitory effects of rottlerin on TPST1 and 2, raised questions about the general sensitivity of TPST
enzymes to ATP-competitive kinase inhibitors. These ﬁndings prompted us to screen the open access PKIS, a
collection of high-quality class-annotated kinase inhibitors assembled as a starting point to discover new chem-
ical probes for enzyme targets. The commonality of the nucleotide-binding site in huge numbers of human
proteins, and shared PAPS cofactor speciﬁcity in sulfotransferases made PKIS an attractive, unbiased resource
Figure 4. Validation and comparison of in vitro recombinant TPST sulfotransferase activities.
(A) Immunoblot of an in vitro sulfotransferase assay using a recombinant GST-tagged CC4-tide. Recombinant, puriﬁed
GST-CC4-tide, or puriﬁed GST alone (1 mg) was incubated at room temperature for 1 h with 1 mg of TPST1 or TPST2 ± 500 mM
PAPS (sulfate donor) or 500 mM ATP (phosphate donor). (B) Immunoblot demonstrating TPST1- and TPST2-dependent
sulfation of GST-CC4-tide at the speciﬁc tyrosine residue sulfated in intact CC4 (Tyr741). The assay was performed with 1 mg
of each TPST enzyme, GST-CC4tide or GST-CC4-tide (Tyr741Phe), and 500 mM PAPS for 1 h at room temperature.
(C) Western blot conﬁrming that monoclonal sulfotyrosine antibody does not cross-react with phosphotyrosine. About 1 mg of
GST-CC4-tide and GST was incubated for 1 h with 2 mg of TPST1 or EphA3 ± 500 mM PAPS or 500 mM ATP. GST CC4-tide
sulfation (top panel), EphA3 autophosphorylation, or GST-CC4-tide phosphorylation (middle panel) is indicated. (D) Detection
of in vitro recombinant FGF7 sulfation by immunoblot. Halo-tagged FGF7 (5 mg) was incubated for 16 h at 20°C with 2 mg of
TPST protein ± 500 mM PAPS or 500 mM ATP, and tyrosine sulfation was detected using a monoclonal sulfotyrosine antibody
(top panel). For all immunblotting-based assays, equal loading of substrate proteins was conﬁrmed by Ponceau S staining
(bottom panels). (E) To assess effects of TPST2 on TPST1 activity, TPST1 (ﬁxed at 0.1 μM, blue symbols) was pre-incubated
with the indicated concentration of TPST2 and assayed in the presence of 10 μM PAPS and 2 μM ﬂuorescent FGF7 peptide.
Peptide sulfation was monitored in real time by mobility analysis, and compared with control reactions lacking TPST2, or with
indicated concentrations of TPST2 lacking TPST1 (red symbols).
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for identifying potential new inhibitors for this family of enzymes. We took a dual-pronged approach for
ligand screening, employing ﬁrstly a rapid TPST1 DSF assay and secondly a TPST1 enzyme assay. For DSF, a
20 μM compound concentration was employed for screening with 1 mM ATP as positive control, and we used
a reproducible cut-off value of ∼ΔTm ± 0.5°C in order to deﬁne a ‘hit’ (Figure 7A). The top compound found
through this approach was GW406108X, and we noted strong thermal shifts in TPST1 by several compounds
belonging to this indole-based kinase inhibitor class (red, Figure 7A and Supplementary Figure S4). Each ‘hit’
compound was next re-screened in a TPST1 enzyme sulfation assay at 40 μM, and the activity remaining com-
pared with DMSO control (Figure 7B). Consistent with our DSF assay, ﬁve of the top seven TPST1 inhibitors
were previously known RAF inhibitors with IC50 values for TPST1 in the low μM range, approximately an
order of magnitude less potent than that of rottlerin (compare Figures 6C and 7C). These compounds were
from two distinct types of previously described RAF inhibitors: derivatives of indole [65] or aza-stilbene [66]
chemical classes. We next conﬁrmed that GW305074X was a low-micromolar inhibitor of tyrosine sulfation by
immunoblotting (Figure 7D), and investigated the rank order of potency for various indole compounds using
GST-CC4-tide tyrosine sulfation, which was compared alongside rottlerin and PAP using the sulfotryosine-
speciﬁc antibody (Figure 7E). Some limited structure–activity relationships emerged from these initial screens,
prompting us to evaluate whether our data permitted us to predict generalised TPST inhibition by other RAF
inhibitors, including clinically approved [67] and probe [68] compounds (Supplementary Figure S4). As shown
in Figure 8A, duplicate assays revealed inhibition at a high (400 μM) concentration by many, but not all, RAF
inhibitors tested, with dabrafenib, RAF-295, ZM336372, sorafenib, and vemurafenib showing essentially com-
plete TPST1 inhibition at this concentration. The titration of each compound conﬁrmed a complex proﬁle of
inhibition, with some RAF inhibitors (e.g. vemurafenib) potentially inducing partial TPST-1 activation at lower
concentrations, and then inhibiting activity at higher concentrations (Figure 8B), perhaps consistent with their
complex mode of interaction with RAF, which includes promotion of dimerisation and activation [69,70]. The
most compelling inhibitory data were obtained with RAF265, a phase I imidazo-benzimidazole RAF inhibitor
[71,72], for which an IC50 value of 6.5 μM towards TPST1 was measured, some 10-fold higher than that of rot-
tlerin (Figure 8B). As shown in Figure 8C, both compounds exhibited dose-dependent inhibition when assayed
Figure 5. Nucleotide-dependent inhibition of TPST1 sulfotransferase activity varies with PAPS.
(A) Dose–response curves and IC50 values for a panel of nucleotides incubated with TPST1 in the presence of 10 mM PAPS
cofactor. TPST1 activity was measured using CC4-tide and normalised to controls containing buffer alone. (B–E)
TPST1-dependent CC4-tide sulfation was measured in the presence of increasing PAPS concentration and a ﬁxed
concentration of (B) 20 mM PAP, (C) 100 mM ATP, (D) 100 mM CoA, or (E) 100 mM dephospho-CoA. All assays were performed
using 0.1 mM TPST1 in the absence of MgCl2.
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in the presence of TPST1 and PAPS using GST-CC4-tide, and inhibition by RAF265 could be competitively
decreased by increasing the concentration of PAPS in the assay, suggesting a partially competitive mode of
inhibition with PAPS (Figure 8D,E).
Docking analysis of TPST ligands
To model the interaction of hit and control TPST1/2 ligands, including rottlerin, suramin, the sorafenib-
derivative RAF265, and GW305074X with TPST1, we employed molecular docking to evaluate potential
binding modes of compounds using the crystal structure of TPST1 (PDB ID: 5WRI). As shown in Figure 9A,
like TPST2 [29], TPST1 possesses two adjacent docking sites in the extended catalytic region that accommodate
binding of substrates, placing the tyrosine-containing substrate (left site) in proximity to the sulfate group of
PAPS (right site). A docking protocol for the sulfation end-product PAP (adenosine-30-50-diphosphate) was
developed that almost perfectly matched the crystallographic binding pose of this ligand for TPST1 (RMSD
0.30 Å, Figure 9B). By comparing experimentally favoured conﬁgurations with those of the crystallised ligands
(PAP and a CC4 peptide poised for sulfation), we were able to conﬁdently dock rottlerin, suramin, RAF265,
and GW305074X into the TPST1 active site. These compounds are predicted to make many stabilising interac-
tions that help explain their ability to act as inhibitors of TPSTs in vitro (Figure 9C–F). For example, rottlerin
(C) and GW305074X (D) are predicted to occupy the peptide-binding site of TPST1, while suramin (E) and
RAF265 (F) span both the peptide and PAPS-binding sites, consistent with the competitive loss of TPST1
inhibition by RAF265 observed as the concentration of PAPS increases in enzyme assays (Figure 8D). In con-
trast, suramin is predicted to form a hydrogen bond with Ser286, while RAF-265 forms hydrogen bonds with
both Ser286 and Leu84.
Discussion
TPSTs catalyse protein sulfation using PAPS as the sulfate group donor, and are thought to possess structural
[29] and biochemical similarities with protein tyrosine kinases relevant to both binding of synthetic substrates
and an ability to modify them enzymatically in vitro [73]. Overlapping sulfate or phosphate modiﬁcations can
potentially occur on the same tyrosine residue when appropriate acidic residues dock the substrate into the
active site for covalent modiﬁcation [26,74]. Although the physiological relevance of combinatorial and com-
petitive tyrosine modiﬁcation on phosphate or sulfate (or nitrate) remains essentially unknown, bioinformatic
analysis incorporating secondary structural analysis predicts that >20 000 context-dependent protein tyrosine
Figure 6. Targeting TPST sulfotransferase activity with small-molecule inhibitors.
(A) Dose–response curves and calculated TPST IC50 values for rottlerin. TPST1 and 2 were incubated with the indicated
concentration of rottlerin in the presence of 10 mM PAPS. TPST sulfotransferase activity towards CC4-tide was normalised to
control reactions containing 1% (v/v) DMSO. (B) Thermal stability of puriﬁed TPST1 or TPST2 (5 mM) was measured in the
presence of 10 mM rottlerin or 500 mM ATP as control. ΔTm values were calculated by DSF as previously described. (C) TPST1
IC50 values for the previously described compounds suramin, aurintricarboxylic acid, and rottlerin were calculated using TPST1
and CC4-tide in the presence of 10 mM PAPS, and activity was normalised to control reactions containing 1% (v/v) DMSO.
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Figure 7. Mining the PKIS inhibitor library for TPST1 inhibitors. Part 1 of 2
(A) Identiﬁcation by DSF of PKIS small-molecule ligands that alter TPST1 thermal stability. TPST1 (5 mM) was screened using
PKIS compounds at a ﬁnal concentration of 20 mM compound and 4% (v/v) DMSO. ΔTm values were calculated by subtracting
the control Tm value (DMSO alone, no inhibitor) from Tm values. Data shown are a scatter plot of the mean ΔTm values from
two independent DSF-based assays. (B) Enzymatic inhibition of TPST1 sulfotransferase activity by selected PKIS compounds.
TPST1 (0.1 mM) was incubated with the appropriate PKIS compound (40 mM) in the presence of 10 mM PAPS for 30 min at
37°C. TPST1 activity was measured using CC4-tide and normalised to 4% (v/v) DMSO control. The chemical class of inhibitor
identiﬁed is colour-coded. (C) Compound dose–response and estimated IC50 values for selected chemical classes of PKIS
inhibitors. TPST1 (0.1 mM) was incubated with increasing concentrations of the indicated inhibitor in the presence of 10 mM
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residues are sulfated in the human proteome [30,31,75]. However, due to a lack of chemical tool compounds,
sulfation is understudied in living organisms, often relying on ‘sledgehammer’ approaches employing non-
speciﬁc reagents such as chlorate or total genetic ablation [36]. The analysis of tyrosine sulfation remains ripe
Figure 7. Mining the PKIS inhibitor library for TPST1 inhibitors. Part 2 of 2
PAPS for 30 min at 37°C. TPST1 activity was measured using CC4-tide and normalised to DMSO controls. The data shown
(and IC50 values) were calculated from duplicate experiments. (D) TPST1 (0.2 mg) was assayed using 1 mg of GST-CC4-tide
and 10 mM PAPS in the presence of the indicated concentrations of GW305074X for 10 min prior to immunoblotting with
monoclonal sulfotyrosine antibody Sulfo-1C-A2. (E) Immunoblots evaluating time dependence of TPST1 sulfotransferase
activity in the presence of a panel of PKIS or several control inhibitors. GST-CC4-tide (1 mg) was incubated for the appropriate
time in the presence of 0.2 mg TPST1, 10 mM PAPS, and a ﬁxed concentration (40 mM) of the indicated inhibitor. After reaction
termination, tyrosine sulfation was subsequently visualised using monoclonal sulfotyrosine antibody (top panel), with equal
GST-CC4-tide loading conﬁrmed by Ponceau S staining (bottom panel). GST-CC4 sulfation was performed for either 15 min
(top panels) or 40 min (bottom panels).
Figure 8. Evaluation of TPST1 inhibition by a panel of RAF kinase inhibitors.
(A) Inhibition of TPST1 by RAF265 and other chemical classes of RAF inhibitor. TPST1 (0.1 mM) was pre-incubated with the
appropriate inhibitor (400 mM) and the assay was initiated with PAPS (10 mM). (B) Dose–response and estimated IC50 values for
TPST1 inhibition by RAF kinase inhibitors. TPST1 (0.1 mM) was pre-incubated with the indicated concentration of compound,
and the assay was initiated with PAPS (10 mM). (C) Immunoblotting of GST-CC4-tide (1 mg) sulfation by TPST1 (1 mg) in the
presence of increasing concentrations of RAF265 or rottlerin. TPST1 was pre-incubated with the indicated concentration of
inhibitor, and assays were performed in the presence of 10 mM PAPS for 15 min at 20°C. (D) Antibody-based quantiﬁcation of
GST-CC4-tide sulfation by TPST1 in the presence of RAF-265 as a function of PAPS concentration. The tyrosine sulfation of
GST-CC4-tide (a measure of TPST1 activity) was quantiﬁed by densitometry with the IMAGE J software. Data were normalised
to sulfation in the presence of 500 mM PAPS and 4% (v/v) DMSO, which represents 100% activity in the absence of the
inhibitor. (E) A representative immunoblot corresponding to the data quantiﬁed in (D) is presented.
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for both technological innovation and the discovery of new classes of sulfotransferase inhibitor [76], in order to
promote new chemical biology approaches in the ﬁeld.
DSF and sulfotransfer analysis of TPST1 and TPST2
In the present paper, we report a simple and rapid method for the detection of TPST-catalysed peptide sulfation
using model substrates fused to an N-terminal ﬂuorophore. The chemical similarity between the phosphate donor
ATP and PAPS, the universal sulfate donor, led us to investigate whether peptide tyrosyl sulfation could be detected
using a high-throughput enzymatic procedure previously validated for phosphorylation catalysed by
ATP-dependent kinases. To isolate pure, enzymatically active recombinant TPST1 and TPST2, both were expressed
at high levels in bacteria, and refolded after puriﬁcation from inclusion bodies using published ‘slow’ procedures
suitable for structural and enzymatic analysis of TPST1 [24] and TPST2 [29]. The afﬁnity of our TPST1 and
TPST2 preparations for the PAPS cofactor was found to be almost identical with that previously reported, and we
conﬁrmed that TPST1 and TPST2 were folded and could bind to a variety of physiological and non-physiological
ligands. These included sulfated PAPS and PAP, the end product of the sulfotransferase reaction (Figure 1 and
Supplementary Figure S1). Protein kinases are also known to bind to the reaction end product of the phospho-
transferase reaction (ADP), which can act as a weak ATP-competitive inhibitor [48]. Our study also revealed that
TPST1 and 2 interact with the 30-phospho-adenosine moiety of the ligand CoA, conﬁrming the availability of the
Figure 9. Molecular docking analysis of TPST1 with small-molecule inhibitor compounds.
(A) Structure of human TPST1 complexed with adenosine-30-50-diphosphate (PAP) and the human CC4-derived substrate
EDFEDYEFD PDB ID: 5WRI (protein rendered in grey cartoon). The inhibitory cofactor PAP (which replaces the physiological
cofactor PAPS) and the co-crystallised CC4 substrate peptide are rendered as coloured sticks. Atoms are coloured grey
(carbon), red (oxygen), blue (nitrogen), or cyan (oxygen of crystallographic water). Black dotted line indicates the close proximity
of the tyrosyl hydroxyl group and PAP. (B) TPST1 docking poses compared. Experimentally derived (PDB ID: 5WRI)
crystallographic carbons (cyan) or our modelled docking carbons (purple) are overlaid for the inhibitory cofactor mimic PAP.
TPST1 was rendered as a cartoon. PAP shown in coloured sticks. Black dotted lines indicate hydrogen bonds. Rottlerin (C),
GW305074X (D), suramin (E), or RAF265 (F) were all docked into human TPST1 (PDB ID: 5WRI), although docking solutions for
each inhibitor could also be made with the very similar TPST2 catalytic domain (PDB ID: 3AP1). Proteins are depicted as
cartoons with the following features: red— α-helix, yellow— β-sheet, green— loop. Docked molecules are coloured as sticks.
Black dotted lines indicate potential hydrogen bonds.
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 2449
Biochemical Journal (2018) 475 2435–2455
https://doi.org/10.1042/BCJ20180266
30-phospho-adenosine docking region in the active site of TPSTs for unrelated ligand binding. To our knowledge,
our studies are the ﬁrst to employ DSF-based thermal shift assays to analyse TPST ligand binding, although these
approaches are also widely used for semi-quantitative ligand-binding analysis of growth factors [45,77], protein
kinase [48,55–57] and pseudokinase [78] domains, BH3 domains [47] and bromodomains [79].
Standard biochemical assays often involve the detection of 35S-based substrate sulfation derived from
35S-labelled PAPS, and require enzymatic cofactor synthesis and time-consuming radioactive solid-phase chro-
matography (typically HPLC) procedures [80,81]. In contrast, our peptide sulfation assay detects modiﬁcation in
real time using a simple mobility shift assay, which is quantiﬁed by comparing the ratio of the sulfated and non-
sulfated ﬂuorescent substrates. This assay employs the EZ-Reader II platform originally developed for the rapid
analysis of peptide phosphorylation, acetylation, or proteolysis [50], and permits the inclusion of high concentra-
tions of non-radioactive cofactors, substrates, and ligands. The coupling of a ﬂuorophore at the peptide
N-terminus, distinct from the site of tyrosine sulfation (Figure 2A), overcomes current limitations with ﬂuores-
cent TPST substrates, in which the ﬂuorophore lies adjacent to the site of sulfation. In the course of our studies,
we established a high reproducibility for this assay and exploited it to probe substrate speciﬁcity and discover
new enzyme inhibitors. We also generated a substrate lacking a key Tyr residue, a dual protein kinase/TPST sub-
strate and model TPST substrates containing acidic residues at the −1 and +1 position relative to the sulfated
Tyr. These allowed us to generate CCR8 and FGF7 substrates for TPST1, which were not substrates for TPST2,
and dual substrates with differential (CC4-tide) or very similar (PSGL1) sulfation kinetics for TPST1 and TPST2.
Based on our initial analyses, we found that TPST2 only sulfated tyrosine-containing peptide substrates with an
acidic residue in both the +1 and −1 position, whereas TPST1-dependent tyrosine sulfation only required a
negative charge to be present in the −1 site (Figure 2). Future work will employ a much larger selection of
peptide substrates to evaluate this preference further, with a goal of deﬁning TPST1 and TPST2 substrate speciﬁ-
city in vitro that can be exploited to help examine the sulfoproteomic datasets emerging from cell-based studies.
New small-molecule TPST1 inhibitors
We conﬁrmed by real-time analysis that TPST ligands act as competitive active-site inhibitors of peptide sulfa-
tion, creating a new impetus to develop novel screening approaches to discover TPST inhibitors. Our ﬁnding
that TPST1 was inhibited at sub-micromolar concentrations by the anti-angiogenic compound suramin, which
has been used clinically to treat River Blindness and African trypanasomiasis [63], and the cellular DNA poly-
merase inhibitor aurintricarboxylic acid [64] was intriguing, and consistent with a very recent report demon-
strating inhibitory activity towards TPSTs [35]. By screening a panel of kinase inhibitors, we found that
rottlerin (also known as mallotoxin) is also a low-micromolar inhibitor of TPST1 and TPST2 in vitro. Rottlerin
was originally identiﬁed as an inhibitor of PKC isozymes [61], but can also act as a sub-micromolar inhibitor
of other protein kinases in vitro [62]. Interestingly, we discovered that all three of these compounds also have
inhibitory activity towards the related PAPS-dependent heparin sulfate 2-O sulfotransferase HS2ST in vitro
[43], allowing us to infer that structural similarities in the PAPS or substrate-binding regions of HS2ST and
TPST1/2 present a binding surface that accommodates small polyanionic compounds, which, like TPST acidic
peptide substrates, presumably bind through electrostatic interactions in the enzyme active site. These ﬁndings
heightened the possibility that other kinase inhibitors might also be serendipitous TPST inhibitors.
To evaluate this hypothesis, we identiﬁed many TPST1 ligands in PKIS. Intriguingly, four of the top seven
hits in this screen belonged to the same benzylidene-1H-inol-2-one (oxindole) c-RAF kinase inhibitor subclass
[65]. Moreover, of the other top 30 TPST inhibitors identiﬁed (TPST1 enzyme inhibition >40% at 20 μM),
GW445015X, GW445017X, and most notably GW458344A, were all potent c-RAF inhibitors, belonging to the
chemically distinct aza-stilbene chemical class [66]. We next conﬁrmed that distinct RAF inhibitors also
possess inhibitory properties towards TPST1. Interestingly, well-validated clinical RAF inhibitors, including
RAF265 (IC50 6.5 μM), vemurafenib (IC50 ∼40 μM), and the much higher micromolar TPST inhibitor sorafenib
(which contains the same 2-arylaminobenzimidazole chemical scaffold found in RAF265, Supplementary
Figure S4), were also TPST1 inhibitors in vitro. These ﬁndings demonstrate that many compounds designed as
RAF inhibitors also have the ability to inhibit TPST1, providing a new impetus to exploit the huge amount of
RAF inhibitor design knowledge available in private and public databases for the design and testing of TPST
inhibitors. In a related paper, we demonstrated cross-reactivity of rottlerin- and oxindole-based (but not
aza-stilbene or other RAF) inhibitors with the glycan sulfotransferases HS2ST [43]. Interestingly, the potency of
HS2ST inhibition by oxindole-based c-RAF inhibitors was some 10-fold lower than that for TPST1, and we
conﬁrmed that TPST RAF inhibitors such as RAF265 and aza-stilbenes did not inhibit HS2ST at any
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).2450
Biochemical Journal (2018) 475 2435–2455
https://doi.org/10.1042/BCJ20180266
concentration tested. These subtle differences suggest that although inhibitor sensitivity to this class of RAF
inhibitors can be shared between two distinct classes of sulfotransferase, opportunities exist for the develop-
ment of both speciﬁc and potent ligands targeted more speciﬁcally towards either HS2ST or TPSTs.
Conclusions
To stimulate progress in implementing chemical biology in the sulfotransferase ﬁeld, careful structure-based
comparison between HS2ST, TPST1/2, and RAF kinase inhibition, and analysis of a wide variety of compound
chemotypes obtained from high-throughput analysis, will be required. Our docking studies with TPST1 suggest
similar binding modes for both rottlerin and the oxindole TPST1 inhibitor GW305074X (Figure 9), while
suramin and RAF265 might feasibly interact with the extended peptide and PAPS cofactor-binding sites. It will
be intriguing to conﬁrm these binding modes through biophysical analysis and structure-guided enzyme muta-
genesis, and to identify drug-binding site residues in sulfotransferases that dictate inhibition. This information
can then be used for careful compound analysis and the generation of drug-resistant alleles for cellular analysis,
using concepts developed for compound target validation in the kinase ﬁeld [82–86]. In the ﬁrst instance, it
will also be important to evaluate whether any of the TPST ligands identiﬁed here, particularly cellular RAF
inhibitors, interfere with protein tyrosine sulfation in cells, since it remains formally possible that some of the
cellular phenotypes and/or clinical effects documented with these compound classes [67] might be explained in
part by ‘off-target’ effects on sulfation-based biology. Cellular inhibition by such non-optimised compounds
will probably depend on several unknown factors, most notably the cellular concentration of PAPS, the rate of
tyrosine sulfation and desulfation, and the relative penetrance of compounds into the Golgi, where modiﬁcation
is thought to occur.
Our work also raises the possibility that TPST inhibitors might be synthesised or repurposed based on work-
ﬂows previously developed for the iteration of the different families of (RAF) kinase inhibitors. Although only
two TPSTs are present in multicellular eukaryotes, the development of speciﬁc inhibitors might be challenging,
given the ∼90% similarity within the active site, the presence of multiple distinct PAPS-dependent sulfotrans-
ferases in vertebrate genomes, and the presence of endogenous competing PAPS present in the cell. However,
in this context, it is useful to recall the rapid development of the kinase inhibitor ﬁeld as an exemplar. Initial
scepticism about the feasibility (or, even, the need) to generate speciﬁc inhibitors of protein kinases has been
largely overcome [87], partly through innovative synthetic approaches, but also by a deep understanding of
mechanistic and structural kinase biology available within the >500 distinct members of the human kinome
[38]. An appreciation that compound polypharmacology, perhaps across multiple enzyme classes, is important
for driving, and predicting, both efﬁcacy and compound side effects for kinase inhibitors [88–90] might also be
useful for the development of TPST inhibitors.
Finally, inhibitor-based interrogation of TPST-dependent tyrosine sulfation could be employed alongside
MS-based sulfoproteomics [32,91]. This could have a signiﬁcant impact in various areas of research by increas-
ing our ability to chemically control and modulate tyrosine sulfation and even manipulate sulfation of speciﬁc
proteins, including those implicated in, for example, infection and inﬂammation. Given the close parallels
between tyrosine sulfation and tyrosine phosphorylation, whose rational targeting rapidly led to the analysis of
large numbers of clinically relevant small-molecule inhibitors [87], we suggest that a new opportunity might
also soon exist to integrate the analysis of TPST with the tools of chemical biology.
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